<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586244</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 24360-901</org_study_id>
    <nct_id>NCT04586244</nct_id>
  </id_info>
  <brief_title>An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma</brief_title>
  <acronym>Optimus</acronym>
  <official_title>An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant&#xD;
      treatment combinations in participants who have muscle-invasive urothelial carcinoma of the&#xD;
      bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical&#xD;
      cystectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be stratified based on Programmed cell Death-Ligand 1 (PD-L1) Combined&#xD;
      Positive Score ( CPS) &lt; 10 and PD-L1 CPS ≥ 10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 24, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic intratumoral changes</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Defined as change from baseline in CD8+ lymphocytes within resected tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 30 days after last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete response</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Defined as percentage of participants with absence of tumor as well as no observed tumor in the nodes post neoadjuvant therapy and pre-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathological response</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Defined as absence of tumor cells determined pre- surgery or in-Situ absence of tumor cells in the nodes and no metastases.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epacadostat will be administered in combination with retifanlimab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>retifanlimab will be administered as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epacadostat will be administered as monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retifanlimab</intervention_name>
    <description>retifanlimab will be administered IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epacadostat</intervention_name>
    <description>epacadostat will be administered daily twice daily orally up to and including day of surgery.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed transitional cell urothelial carcinoma. Participants with&#xD;
             mixed histologies are required to have a dominant (ie, 50% at least) transitional cell&#xD;
             pattern.&#xD;
&#xD;
        Clinical stage T2-T3b, N0, M0 muscle invasive urothelial carcinoma by CT (or MRI) +&#xD;
        Positron Emission Tomography (PET)/CT (Stage II-IIIA per American Joint Committee on Cancer&#xD;
        (American Joint Committee on Cancer (AJCC) 2018)).&#xD;
&#xD;
          -  Ineligible for cisplatin therapy per modified Galsky criteria with exclusion of&#xD;
             Eastern Cooperative Oncology Group( ECOG) PS 2 participants&#xD;
&#xD;
          -  Participants who refuse cisplatin-based therapy.&#xD;
&#xD;
          -  Eligible for radical cystectomy&#xD;
&#xD;
          -  Residual disease after TURBT (eg, surgical opinion, cystoscopy or radiological&#xD;
             presence).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status( PS) 0 or 1.&#xD;
&#xD;
          -  Pretreatment tumor biopsy must be a tumor block or 20 unstained slides from biopsy of&#xD;
             primary tumor containing at least 20% tumor.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other study in which receipt of an investigational study drug or&#xD;
             device occurred within 28 days or 5 half-lives (whichever is longer) before first&#xD;
             dose.&#xD;
&#xD;
          -  Previously received systemic therapy for bladder cancer or received prior treatment&#xD;
             with checkpoint inhibitor agents (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or&#xD;
             anti-CTLA-4).&#xD;
&#xD;
          -  Evidence of measurable nodal or metastatic disease.&#xD;
&#xD;
          -  Concurrent anticancer therapy.&#xD;
&#xD;
          -  Has had major surgery within 4 weeks before enrollment (C1D1).&#xD;
&#xD;
          -  Has had known additional malignancy other than muscle-invasive Urothelial Bladder&#xD;
             Cancer ( miUBC) that is progressing or requires active treatment, along with some&#xD;
             protocol exceptions.&#xD;
&#xD;
          -  Has active autoimmune disease requiring systemic immunosuppression with&#xD;
             corticosteroids (&gt; 10 mg daily doses of prednisone or equivalent) or immunosuppressive&#xD;
             drugs within 2 years of Day 1 of study treatment.&#xD;
&#xD;
          -  Participants with laboratory values outside of protocol defined range.&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic immunosuppression in excess of&#xD;
             physiologic maintenance doses of corticosteroids (&gt; 10 mg/day of prednisone or&#xD;
             equivalent).&#xD;
&#xD;
          -  Has a known active hepatitis B (HBsAg reactive) or hepatitis C or HIV,HBV, HCV or&#xD;
             hepatitis virus coinfection.&#xD;
&#xD;
          -  Participants with HIV+ disease that don't have undetectable viral load along with&#xD;
             other protocol exceptions.&#xD;
&#xD;
          -  Has known carcinomatous meningitis.&#xD;
&#xD;
          -  Active infection requiring systemic antibiotics ≤ 14 days from first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Participants with known or suspected COVID-19 infection.&#xD;
&#xD;
          -  Use of probiotics within 28 days from first dose of study drug.&#xD;
&#xD;
          -  Current use of prohibited medication as per protocol.&#xD;
&#xD;
          -  History or presence of an abnormal ECG that, in the investigator's opinion, is&#xD;
             clinically meaningful.&#xD;
&#xD;
          -  History of a gastrointestinal condition (eg, inflammatory bowel disease, Crohn's&#xD;
             disease, ulcerative colitis) that may affect oral drug absorption.&#xD;
&#xD;
          -  Participants with impaired cardiac function or clinically significant cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle-invasive cisplatin-ineligible</keyword>
  <keyword>urothelial carcinoma of the bladder</keyword>
  <keyword>radical cystectomy.</keyword>
  <keyword>epacadostat</keyword>
  <keyword>retifanlimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

